Release Summary

FDA Approves Merck’s ZINPLAVA (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection in Adult Patients Receiving Antibacterial Drug Treatment for CDI Who Are at High Risk of Recurrence

Merck